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The prevalence andmorbidity associated with osteoporosis and fractures in patients with spina bifida (SB) highlight
the importance of osteoporosis prevention and treatment in early childhood; however, the issue has received little
attention. The method for the selection of appropriate patients for drug treatment has not been clarified.
Objective: To review the literature concerning fracture risks and low bone density in paediatric patients with SB.
We looked for studies describing state-of-the-art treatments and for prevention of secondary osteoporosis.
Methods: Articles were identified through a search in the electronic database (PUBMED) supplemented with
reviews of the reference lists of selected papers. The main outcome measures were incidence of fractures
and risk factors for fracture, an association between bone mineral density (BMD) and occurrence of fracture,
risk factors of low BMD, and effects of pharmacological and non-pharmacological treatments on BMD and
on the incidence of fractures. We considered as a secondary outcome the occurrence of fractures in relation
to the mechanism of injury.
Results: Results indicated that patients with SB are at increased risk for fractures and low BMD. Risk factors that
may predispose patients to fractures include higher levels of neurological involvement, non-ambulatory status,
physical inactivity, hypercalciuria, higher body fat levels, contractures, and a previous spontaneous fracture.
Limitations were observed in the number and quality of studies concerning osteoporosis prevention and
treatment in paediatric patients with SB. The safety and efficiency of drugs to treat osteoporosis in adults
have not been evaluated satisfactorily in children with SB.
Keywords: Spina bifida, Spinal dysraphism, Myelomeningocele, Disability, Densitometry, Bisphosphonates, Bone mineral density, Fracture, Osteoporosis,
Hypercalciuria, Paraplegia, Treatment, Prevention, Child, Adolescence
Introduction
In congenital paraplegia caused by myelomeningocele
(MMC), the body lacks the usual axial load on the
legs, which have decreased sensation and muscular
activity.1 These deficits can impair ambulation and
lead to physical inactivity and osteoporosis,2,3 which
predisposes the patient to fragility fractures. In patients
who are already disabled and subject to frequent surgi-
cal interventions, osteoporosis-related fractures result
in a vicious cycle in which further immobilization
heightens the risk of multiple fractures.2–7 In childhood
and adolescence, the formation of bone prevails;8
consequently, childhood and adolescence constitute
critical periods for the foundation of a lifetime of
bone health. Failure to achieve peak bone mass has
been linked to an increased risk of osteoporosis and
fracture in adulthood. Therefore, preventing osteo-
porosis and identifying and treating children with
established osteoporosis could be an important strategy
for achieving peak bone mass in patients with spina
bifida (SB).9
Because fractures are a widespread problem in this
population, determining which risk factors will identify
the individuals more likely to suffer fractures is an extre-
mely important task that is critical for the subsequent
determination for intervention.
We reviewed the literature regarding the prevention
and treatment of osteoporosis in patients with SB and
discuss which risk factors for fractures and low bone
mineral density (BMD) are associated with SB in
paediatric populations.
Study design and methods
To examine the current scientific recommendations
regarding osteoporosis and the prevention of fractures
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in paediatric patients with SB, we performed a systema-
tic electronic search of papers published from 1970
through 2011 in a major electronic database
(MEDLINE/PUBMED) focusing on three domains:
(1) the incidence and risk factors of fractures, (2)
BMD, and (3) the prevention and treatment of osteo-
porosis. The last search was performed on 10 June
2011. Promising reports were identified through the
evaluation of abstracts and MeSH terms.
Findings were supplemented by reviewing the refer-
ence lists of selected papers.
Only original studies in humans were selected. For
BMD and treatment studies, selected studies included
heterogeneous data and patients with SB. For incidence
and risk factors of fractures, studies were excluded if
they included patients without SB. To examine the inci-
dence and risk factors of fractures and BMD studies,
case reports were eliminated. For BMD studies,
studies with medical interventions were excluded.
Articles were excluded if the full article was not freely
available in PUBMED or in Portuguese libraries or if
studies only included adults.
There were three main outcomes of interest: (1) the
incidence of fractures and risk factors for fractures,
(2) an association among BMD and the occurrence
of fractures and risk factors of low BMD, and (3) the
effects of pharmacological and non-pharmacological
treatments on BMD and the incidence of fractures. A
secondary outcome was the occurrence of fractures in
relation to the mechanism of injury. The searches
were restricted to articles published in English.
Keywords and search criteria used to identify studies
on the incidence and risk of fractures were performed
in the following format: ‘Spinal Dysraphism,’ OR
‘Meningomyelocele,’ AND ‘Fracture’. We restricted
our search to articles in which ‘Fracture’ was a
MeSH Major Topic.
Next, we searched using the keywords ‘Spinal
Dysraphism,’ ‘Meningomyelocele,’ and
‘Myelomeningocele,’ using OR as the combination
term, and we combined these terms with ‘Bone density’
using AND as the combination term. Finally, we used
the following searches in our review to analyse pharmaco-






‘Myelomeningocele’[All Fields] OR ‘Spina bifida’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
‘Bone density’[All Fields] AND ‘Prevention’[All Fields]
• Spinal Dysraphism
• Walking
• Bone and Bones
• ((‘Spinal Dysraphism’[Mesh] OR ‘Meningomyelocele’




• ‘Myelomeningocele’[All Fields] OR ‘Spina bifida’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
(‘Osteoporosis’[All Fields] OR (‘Bone’[All Fields]
AND ‘Walking’[All Fields])) AND (‘humans’[MeSH
Terms] AND English[lang] AND (‘1970/01/
01’[PDAT]: ‘2011/06/10’[PDAT]))
• Vibration




• ‘Myelomeningocele’[All Fields] OR ‘Spina bifida’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
(‘Osteoporosis’[All Fields] OR ‘Bone density’[All
Fields]) AND (‘Standing’[All Fields] OR ‘Vibrating
platform’[All Fields] OR ‘Vibration’[All Fields])
• Calcium
• (‘Spinal Dysraphism’[Mesh] OR ‘Meningomyelocele’
[Mesh]) AND ‘Calcium’[Mesh]
• Vitamin D
• (‘Spinal Dysraphism’[Mesh] OR ‘Meningomyelocele’
[Mesh]) AND ‘Vitamin D’[Mesh]
• Diphosphonates
• ((‘Spinal Dysraphism’[Mesh]) OR ‘Meningomyelocele’
[Mesh]) AND ‘Diphosphonates’[Mesh]
• Treatment
• ‘Myelomeningocele’[All Fields] OR ‘Spina bifida’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
(‘Bone density’[All Fields] OR Osteoporosis [All
Fields]) AND ‘Treatment’[All Fields]
• ‘Spina bifida’[All Fields] OR ‘Myelomeningocele’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
(‘Calcium’[All Fields] OR ‘Vitamin D’[All Fields] OR
‘Diphosphonates’[All Fields]) AND (‘1970/01/
01’[PDAT] : ‘2011/06/10’[PDAT]) AND (‘humans’
[MeSH Terms] AND English[lang])
In a secondary search, to identify studies with patients
with SB, we extended our search to English language
articles from the last 10 years including patients with
disabilities who were up to 18 years old.
1. Osteoporosis/Subheading
2. (‘Osteoporosis/drug therapy’[Majr] OR
‘Osteoporosis/prevention and control’[Majr]) AND
(‘humans’[MeSH Terms] AND English[lang] AND
(‘infant’[MeSH Terms] OR ‘child’[MeSH Terms] OR
‘adolescent’[MeSH Terms]) AND ‘2001/06/
07’[PDat] : ‘2011/06/04’[PDat])
3. Disabled children
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4. Osteoporosis
5. Prevention
6. ((‘Disabled Children’[Mesh]) AND ‘Osteoporosis’
[Mesh]) AND ‘prevention and control’ [Subheading]
For abstracts meeting the goals of this review, we down-
loaded the full articles.
Results
In the firstdomain titled, ‘incidenceandriskof fracture,’ the
search provided 37 articles, but only 16 met the inclusion
criteria (Akbar, 201010; Marreiros, 20104; Okurowska-
Zawada, 200911; Dosa, 200712; Khoury, 200213; Parsch,
19911; Boytim, 199114; Lock, 198915; Drabu, 198516;
Kumar, 198417; Anschuetz, 19843; Reikerås O, 198118;
Drummond 19816; Townsend, 197919; Quilis, 197420;
Korhonen, 197121). By reviewing the reference lists of
selected papers, we selected two additional articles
(Drennan, 197122; James, 197023) (Table 1).
A second search focusing on BMD yielded 25 articles,
but 13 records failed to meet the inclusion criteria.
Twelve articles met the inclusion criteria (Szalay, 201024;
Apkon, 200925; Okurowska-Zawada, 200911; Ausili,
200826; Taskinen, 200727; Boylu, 200628; Pluskiewicz,
200429; Tuckerman, 200230; Mingin, 200231; Quan,
19985; Koch, 199232; Rosenstein, 19877) (Table 2). The
articles Pluskiewicz, 200429 and Tucherman, 200230 were
not freely available in Portuguese libraries; therefore, we
considered only 10 articles.
Finally, for the ‘Prevention and nonpharmacological
and pharmacological treatment of osteoporosis’
review, we initiated our search by focusing on random-
ized, quasi-randomized, and non-randomized con-
trolled trials and cohort and case-control studies.
Because of the low number of studies identified, we con-
sidered case studies and case series. We inspected 50
articles from the searches conducted, but only four
met the inclusion criteria (Mazur, 198933; Quan,
200334; Sholas, 200535; Ausili, 200826) (Table 3).
Because all of the studies had small sample sizes and
because only a limited number of controlled studies in
this clinical research area have been performed, to
increase the number of child patients in the review, the
search was extended to other paediatric diseases com-
monly seen in non-ambulatory patients to identify
studies with heterogeneous data including patients
with SB. This search provided one additional article
that met the requirements (Steelman, 200336) (Table 4).
An article that met our inclusion criteria, but was not
obtained using the search strategy was selected (Liptak,
199237). Thus, in the section review titled, ‘prevention
and treatment of osteoporosis,’ six articles met the eligi-
bility criteria.
Likewise, we selected some general articles not focus-
ing on SB to introduce different topics and to identify
fields in which more research is needed in SB. A total
of 89 articles were selected for analysis.
Frequency of fractures in SB
Prior studies have demonstrated an 11–30% frequency of
fractures in paediatric patients with SB.4,10,15,20,22,23 In
SB, fractures occur more frequently below the level of
neurological involvement in the paralysed lower extremi-
ties, which can be caused by a lack of vertical load.1,10
The most common fracture site is the distal femur.4
Occurrence of fractures in relation to the
mechanism of injury
Many fractures result from minor stress or are spon-
taneous.1,4,10,15,18,19,21 Thus, the true incidence of frac-
tures is probably higher than presently
Table 1 Search strategy used
Incidence and risk factors of fractures Articles
(‘Spinal Dysraphism’[Mesh] OR
‘Meningomyelocele’[Mesh]) AND ‘Fractures,
Bone’[Majr] AND (‘humans’[MeSH Terms] AND
English[lang] AND (‘1970/01/01’[PDAT] :
‘2011/06/10’[PDAT]))
37 records identified on PUBMED
21 reports excluded
8, Case reports (Kiymaz, 2005;
Asirdizer, 2005; Blanco, 1999; Johnson,
1998; Hes, 1997; Dirschl, 1992;
Montgomery, 1984; Sachdev, 1981)
1, Review articles (Westcott, 1992)
11, Other subject (Szalay, 2010; Akbar,
2009; Laidlaw, 1998; Saleh, 1995;
Blanda, 1993; Pomeranz, 1991; Feiwell,
1980; Rodgers, 1997; Wolverson, 1981;
Wenger, 1980; Repasky, 1976)
1, Fractures not associated to SB (Hyre,
1989)
18 record identified that met all eligibility
requirements
16, reports selected through PUBMED
(Akbar, 2010; Marreiros, 2010;
Okurowska-Zawada, 2009; Dosa,
2007; Khoury, 2002; Parsch, 1991;
Boytim, 1991; Lock, 1989; Drabu,
1985; Anschuetz, 1984; Kumar, 1984;
Reikerås, 1981; Drummond 1981;
Townsend, 1979; Quilis, 1974;
Korhonen, 1971)
2, selected through the reference lists
of selected papers (Drennan, 1971;
James, 1970)
Total: 37 records 18 records identified that met all
eligibility requirements
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recorded because not all fractures are recognized.17
Akbar et al. analysed the records of 862 patients with
MMC (retrospective cross-sectional study) and detected
170 fractures (n= 92). The aetiologies of the fractures
were the following: fall (35%), transfer (28%), cast
immobilization (37%), and unknown (21%).10 In our
previous study, we showed that spontaneous fractures
were the principal mechanism of injury (64.4%).4
Parsch et al. have detected 261 fractures in 173 patients
from a sample of 1414 patients followed over a 15-year
period (1975–1989). In 35% of the cases, the fractures
occurred spontaneously. Only 5% of all the fractures
were associated with adequate trauma.1 Lock et al.
detected 66 fractures in 37 of 186 patients.
Only seven (9%) were associated with a history of
known trauma.15
The results of all these studies suggest the importance
of fragility fracture in this population and that these
fractures are amenable to measures of prevention.
Fracture risk assessment in SB patients
SB is a complex disease that involves several organ
systems; thus, it requires an individualized approach
for the clinical assessment of fracture risk. Evidence
has shown that multiple risk factors may act indepen-
dently or in combination to increase the fracture risk.
The importance of each of these risks is still undefined.
Neurological level of involvement and
ambulatory status
There is considerable evidence linking neurological
involvement and ambulatory status with fracture risk.
Fractures occur more frequently with a higher level of
neurological involvement1,4,10,14,15 and in non-ambulat-
ory patients.4,10 James verified that in asymmetrically
affected patients with SB, the paralytic limb was more
likely to be fractured than the active limb.23
Boytim et al. retrospectively reviewed neonatal
fractures in a group of 80 newborn patients with
SB over a 4-year period. Of the six patients with frac-
tures in the neonatal period, three had high-level neuro-
logical involvement (thoracic or L1), three had an
intermediate level (L3), and all had significant
contractures.14
Environmental factors
Okurowska-Zawada et al. showed that body fat levels
were higher in MMC patients with fractures than in
those without fractures.11 Body mass index (BMI) can
be difficult to evaluate in patients with MMC because
of the scoliosis, the presence of contracture in the
lower extremities and their altered dimensions and
growth delay.38,39 Previous studies from general paedia-
tric populations have reported that maternal dietary
folate intake during pregnancy positively correlates
with BMD of the child.40
Table 2 Search strategy used






2, BMD focusing, but not available
(Pluskiewicz, 2004; Tuckerman, 2002)
1, Adult study (Valtonen, 2006)
1, Case reports (Asirdizer, 2005)
1, Review articles (Mingin, 2004)
1, Medical intervention (Quan, 2003)
8 records identified that met all eligibility
requirements: (Szalay, 2010; Okurowska-
Zawada, 2009; Apkon, 2009; Ausili,
2008; Boylu, 2006; Mingin, 2002; Quan,
1998; Koch, 1992)
Spina bifida OR Myelomeningocele AND
Bone density
(‘spinal dysraphism’[MeSH Terms] OR
(‘spinal’[All Fields] AND ‘dysraphism’[All
Fields]) OR ‘spinal dysraphism’[All Fields]
OR (‘spina’[All Fields] AND
‘bifida’[All Fields]) OR ‘spina bifida’[All
Fields]) OR (‘meningomyelocele’[MeSH
Terms] OR ‘meningomyelocele’[All Fields]
OR ‘myelomeningocele’[All Fields]) AND
(‘bone density’[MeSH Terms] OR (‘bone’[All
Fields] AND ‘density’[All Fields])
OR ‘bone density’[All Fields])
25 records identified
15 records excluded
2, BMD focusing, but not available
(Pluskiewicz, 2004; Tuckerman, 2002)
3, Non-English articles (Funk, 2011;
Bellotti, 2009; Torbus, 2002)
2, Case reports (Miyano, 2009;
Asirdizer, 2005)
1, Low BMD not associated with SB
(Hafez, 2003)
1, Adult study (Valtonen, 2006)
1, Review articles (Mingin, 2004)
1, Medical intervention (Quan, 2003)
4, Other subject (Hermann-Kleiter,
2009; Semler, 2007; Patel, 1987;
Fulford, 1975)
10 records identified that met all eligibility
requirements:
(Taskinen, 2007; Rosenstein, 1987)
and 8 were duplicate:
(Szalay, 2010; Okurowska-Zawada, 2009;
Apkon, 2009; Ausili, 2008; Boylu, 2006;
Mingin, 2002; Quan, 1998; Koch, 1992)
Total: 25 records identified 10 records identified that met all eligibility
requirements
Marreiros et al. Osteoporosis in spina bifida
The Journal of Spinal Cord Medicine 2012 VOL. 35 NO. 112
Table 3 Search strategy used
Prevention and treatment of osteoporosis Articles
‘Myelomeningocele’[All Fields] OR ‘Spina bifida’[All
Fields] OR ‘Meningomyelocele’




2, No intervention (Taskinen, 2007; Mingin, 2002)






AND ‘Bone and Bones’[Mesh]
8 records identified
8 records excluded
1, Non-English studies (Jo´z´wiak, 2007)
1, Review articles (Wright, 2011)
6, Other subject (Geertzen, 2009; Nguyen, 2004;







2, Other subject (Semler, 2007; VanSickle, 2001)
—
‘Myelomeningocele’[All Fields] OR ‘Spina bifida’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
(‘Osteoporosis’[All Fields] OR (‘Bone’[All Fields]
AND ‘Walking’[All Fields])) AND (‘humans’[MeSH




6, Other subject (Mountain, 2010; Geertzen,
2009; Semler, 2007; Brasili, 1997; Fraser, 1993;
Dickel, 1989)
7, No intervention (Marreiros, 2010; Okurowska-
Zawada, 2009; Apkon, 2009; Taskinen, 2007;
Quan, 1998; Anschuetz, 1984; Osebold, 1982)
1, Adult patients (Valtonen, 2006)
3, Review articles (Webb, 2010; Lubicky, 2005;
Roussos, 2001)
2 records identified
that met all eligibility
requirements (Ausili,
2008; Mazur, 1981)
‘Myelomeningocele’[All Fields] OR ‘Spina bifida’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
(‘Osteoporosis’[All Fields] OR ‘Bone density’[All
Fields]) AND (‘Standing’[All Fields] OR ‘Vibrating
platform’[All Fields] OR ‘Vibration’[All Fields])
2 record identified
2 records excluded






9, No intervention (Kinoshita, 2010; Okurowska-
Zawada, 2009; Ozard, 2008; Mingin, 2002; Quan,
1998; Pettit, 1980; Lowe, 1971; Wit, 1970;
Fedrick, 1970)














1, Other subject (Semler, 2007)
1, No intervention (Duprez, 1996)
1, Review articles (Oakley, 1984)
—
‘Myelomeningocele’[All Fields] OR ‘Spina bifida’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
(‘Bone density’[All Fields] OR Osteoporosis [All
Fields]) AND ‘Treatment’[All Fields]
7 records identified
6 records excluded
2, No intervention (Marreiros, 2010; Anschuetz,
1984)
3, Other subject (Funk, 2011; Semler, 2007;
Osebold, 1982)
1, Review articles (Lubicky, 2005)
1 duplicate record




‘Spina bifida’[All Fields] OR ‘Myelomeningocele’[All
Fields] OR ‘Meningomyelocele’[All Fields] AND
(‘Calcium’[All Fields] OR ‘Vitamin D’[All Fields] OR
‘Diphosphonates’[All Fields]) AND (‘1970/01/01’
[PDAT] : ‘2011/06/10’[PDAT]) AND (‘humans’
[MeSH Terms] AND English[lang])
23 records identified
22 articles excluded
14, Other subject (Kinoshita, 2010; Semler, 2007;
Matlaga, 2006; Rueffert, 2004; Quan, 2003;
Patwardhan, 2002; Bound, 1997; Litman, 1996;
Osborn, 1989; Petersen, 1987; Pettit, 1980;
Griffiths, 1980; Pettit, 1979; Elwood, 1977)
1, Review articles (Oakley, 1984)
6, No intervention (Okurowska-Zawada, 2009;
Apkon, 2009; Ozard, 2008; Taskinen, 2007;
Mingin, 2002; Quan, 1998)
1, Low BMD not associated with SB (Hafez, 2003)




Total: 50 records identified 4 records identified
that met all eligibility
requirements
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Association between fractures and prolonged
inactivity
In paediatric patients with SB, there is an association
between fractures and prolonged inactivity secondary
to cast immobilization and operative orthopaedic pro-
cedures, a relationship that highlights the need for
careful preoperative selection of patients whose clinical
backgrounds may increase their fracture
risk.1,3,4,6,10,13,15,16,18,20–22
Laboratory parameters
Okurowska-Zawada et al. identified an association
between the incidence of fractures in children with
MMC and increased levels of calcium in a 24-hour
urine sample.11
Genetic predisposition to low BMD
Occurrence of fractures varies even among children with
SB with similar levels of neurological involvement and
ambulatory status. Among wheelchair users with
higher levels of paralysis with a significant number of
orthopaedic interventions and postoperative inactivity,
some suffer multiple pathological fractures, while
others do not. The propensity for fractures could
reflect skeletal weakness or lower BMD associated
with environmental factors, body mass, hormonal
imbalance, or genetic factors.9,41
We did not find any studies evaluating the relation-
ship between genetic factors and low BMD in paediatric
patients with SB. Steer et al. observed an allele-dose
association between the C677T MTHFR genotype
and spinal BMD in children.42 The C677T homozygos-
ity has been associated with a moderately increased risk
of SB43 and early, recurrent paediatric strokes.44
To our knowledge, no study has investigated the influ-
ence of the C677T MTHFR polymorphism on fracture
frequency in paediatric patients with SB.
Risk factors associated with a second fracture
According to our recently published results, patients
with SB who were partially ambulatory and had lower
lumbar motor involvement have a 5% risk of a second
fracture, whereas non-ambulatory wheelchair users,
who were totally dependent on their wheelchair with
thoracic motor involvement, had a 74% risk.4 The
lesion level and ambulatory status are useful for identi-
fying the high-risk group but are not precise enough
because multiple variables confound these factors. It
has been documented that paediatric patients with SB
who sustain a spontaneous fracture are at high risk of
having future fractures.4 It is therefore crucial to identify
the propensity for multiple fractures early in a child’s
life.
Factors not associated with fractures
Factors that were not related to the occurrence of frac-
tures in SB included sex,4,10–12 syringomyelia,4 and neu-
rosurgical interventions.1,4
Dosa et al. found that while neither shunted hydro-
cephalus nor cognitive subscores on the Functional
Independence Measure were associated with fractures.12
Okurowska-Zawada et al. did not detect a correlation
between parathyroid hormone (PTH) and bone for-
mation markers (bone-specific alkaline phosphatase)
and the occurrence of fractures.11
Risk factors of fractures not yet evaluated
To date, no studies have examined this population’s frac-
ture risk in relation to the following factors: family
history of fractures, mother’s folic acid intake and
tobacco use during pregnancy, history of breastfeeding,
calcium, vitamin D and milk intake, vitamin D stores,
soft drink and fruit juice consumption, chronic use of
medications known to interfere with bone mineral depo-
sition (glucocorticoids and anticonvulsants), lean body
mass, exercise habits, smoking habits, susceptibility to
falls, chronic kidney insufficiency with metabolic acido-
sis, hormonal status, and genetics. To our knowledge,
there are no studies assessing the bone resorption by
urinary markers, such as pyridinoline/deoxypyridino-
line or n- and c-telopeptides, or bone formation
markers, such as osteocalcin.
Table 4 Search strategy used
Prevention and treatment of osteoporosis Articles
(‘Osteoporosis/drug therapy’[Majr] OR ‘Osteoporosis/prevention and
control’[Majr]) AND (‘humans’[MeSH Terms] AND English[lang]





1 record identified that met all
eligibility requirement
1 article included (Steelman,
2003)
((‘Disabled Children’[Mesh]) AND ‘Osteoporosis’




1 record identified that met all
eligibility requirements
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Of the many independent variables that have been
tested, those reported to influence fracture risk are
listed in Table 5.
BMD assessment
The most widely validated technique for assessing BMD
is dual-energy X-ray absorptiometry (DXA).45 The
Z-score, which is defined as the number of standard
deviations above or below the average BMD for age-
and sex-matched controls, is often used to determine
how a child’s BMD compares with other children.46
Few studies testing BMD have been conducted in pae-
diatric SB patients. Ausili et al. investigated 60 patients
with MMC aged 5–14 years old (22 ambulatory and 38
non-ambulatory) and detected that BMD was lower in
the non-ambulatory group than in the ambulatory
group.26
Apkon and colleagues have done a cross-sectional
observational study, analysed BMD of the femoral
neck and whole body using DXA in children with
MMC (age range: 4–18 years) and detected low BMD
at the femoral neck in nine of 21 children (42.9%). A sig-
nificant relationship was found between low femoral
neck BMD in children who are wheelchair users, and
a trend towards improved femoral neck BMD was
found in children with lower neurological levels of invol-
vement. No relationship between a history of fractures
and low BMD was described. The authors hypothesized
that this finding may have been due to the mean age of
the studied children (9 years, 8 months).25 Rosenstein
et al. also evaluated BMD using single-photon absorp-
tiometry in 80 patients with MMC aged 1.3–21.7
years and found that both patients with higher-level
neurological involvement and non-ambulatory patients
had lower BMDs than ambulatory patients and those
with lower-level neurological involvement. In this
cohort, no correlation between BMD and the presence
of single or multiple fractures was identified. The
mean age of patients (9.1 years) was similar to the
patients in the study by Apkon et al.7 Consistent with
these findings, Okurowska-Zawada et al. did not ident-
ify significant differences in BMD Z-scores between the
fracture and non-fracture groups.11 Szalay et al. have
analysed 37 patients with SB using DXA scans and
were unable to identify an association between Z-score
and fracture due to small sample size.24
In a study that included 35 patients with MMC aged
6–19 years, randomly chosen, Quan et al. used single-
photon absorptiometry and detected low BMD in the
radius, a bone that is often used extensively in full-
time wheelchair users. The authors hypothesized that
overall physical inactivity may have a systemic effect
on total body bone mineralization and influence the
mineralization of bones not affected directly by the
neurological lesions. The urinary calcium excretion of
non-ambulators was higher compared to ambulators
and likely contributed to their decreased BMD. In dis-
agreement with the previous studies, the authors docu-
mented that patients with fractures had greatly
diminished BMD compared to those without fractures;
however, enrolled patients were slightly older (average
age was 11.1).5 A limitation of this study is its evaluation
of BMD in the radius, which is less often fractured in
this population.
Most of the studies analysed did not support an associ-
ation between a history of fractures and low BMD in
young children. This finding can have important clinical
implications, since treating low BMD may not improve
the incidence of fractures in young children with SB.25
Total body BMC increases nearly three-fold in
females and more than triples in males between 8 and
17 years of age.8 Rosenstein and colleagues documented
that the effect of neurological level in BMD in the lower-
extremity change with age. Tibial and metatarsal density
was greater in those with more distal neurological levels
at all ages, but the difference was proportionally larger
in older patients.7 Thus, it is possible that the differences
in the lower age group could be related to bone strength
without repercussions in BMD analysis by DXA. In
older children, the differences in BMD might be detect-
able with DXA. The ideal age for BMD evaluation to
predict the occurrence of fractures is not yet known.
The low number, the limited sample size, and the
retrospective and retrospective/cross-sectional nature
of the available studies preclude definitive conclusions
about the relationship between low BMD and fracture
risk in this population.
Patients who require bladder augmentation are
prone to the development of metabolic acidosis.32
Comparisons between MMC children who underwent
conduit urinary diversion (ileal or colonic) or were
managed with intermittent catheterization showed no
significant difference in BMD.32 In a comparison of
BMD in MMC children with or without bladder
Table 5 Etiological factors contributing to fracture risk in
paediatric patients with spina bifida
1. Personal history of spontaneous fracture4
2. Non-ambulatory status4,10
3. Higher level of neurological involvement1,4,10,14,15




7. Higher body fat levels11
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augmentation, age- and sex-matched MMC children did
not show any significant differences.31
Boylu et al. evaluated BMD after ileal augmentation
cystoplasty in children with and without MMC and
identified a significant difference between the two
groups even though their mean creatinine, pH, and
bicarbonate levels were similar. The data suggested
that lower BMD depends more on the underlying neuro-
logic pathology and its locomotor consequences than
enterocystoplasty.28 This conclusion was supported by
a second study, which described skeletal health after
intestinal bladder augmentation.27
Indication and timing of BMD assessment
BMD evaluation may be an essential clinical tool to
identify patients with SB who are at risk for fracture
and may benefit from a direct bone health program;24
however, there is no standard approach to measuring
BMD in this population. An expert panel consensus
from the International Society for Clinical
Densitometry (ISCD) in 2007 reported that in children
with chronic immobilization, spine and total body less
head (TBLH) BMC and areal BMD should be
measured at fracture presentation.47 Conventional
radiographic findings compatible with osteopenia may
also prompt performing a DXA scan.45,48 Other indi-
cations for DXA evaluation include chronic disease
with possible secondary effects on skeletal maturity,
chronic use of a medication known to interfere with
bone mineral accrual, and prolonged immobilization.48
The British Pediatric and Adolescent Bone Group
has recommended that a DXA assessment should be
considered for children with conditions that put
them at risk of low BMD if they have a history of
low trauma or recurrent fractures, back pain, spinal
deformity, loss of height, change in mobility status, or
malnutrition.49 The ideal time to evaluate children
with chronic, bone-impacting disease is unknown.
Scans should not be performed more than once every
12 months, except for research to determine new
drug therapies, for monitoring the response to a
pharmacological intervention or evaluating worsening
disease.45,49,50 The minimal time interval between
bone density measurements to monitor treatment with
a bone-active agent or disease processes is 6 months,
and assessments should be performed using the same
machine and software.47
DXA limitations in SB
Despite the wide use of DXA, the technique does have
several limitations. First, DXA does not discriminate
between cortical bone and trabecular or cancellous
bone.41,46,48,50,51 It has a limited ability to assess
certain structural characteristics of bone that affect
strength (e.g., material properties, protein content, geo-
metry and bone size).51 DXA scans in only two direc-
tions (length and width) yield only an areal BMD
value. This areal density provides an incomplete correc-
tion for size because it does not provide information
about bone depth. Areal bone density is inherently
related to the size of the individual; thus, lower BMDs
are expected in shorter children compared to taller
ones, who are expected to have more bone mineraliz-
ation because they have larger bones.41,45,46,51 In chil-
dren with SB, the delay in growth is important
because individuals with SB are often short for their
age.38 Small children may have low BMDs either
because they have smaller bones or they have less bone
mineralization than the size of their bones would
predict.52–54
Another specific issue in children with MMC and
hydrocephalus is precocious puberty,55,56 which may
interfere with BMD.24 Thus, the results of DXA in pae-
diatric patients with SB should be interpreted with care
by physicians who understand the influence of bone size,
skeletal and sexual maturation, and body composition
on BMC and BMD.41
For clinical use, scans of multiple regions of interest
are preferred over whole-body scans.57 In fact, whole-
body scans are difficult to interpret and are often
subject to artefacts. BMD may be difficult to assess
because of heterotopic ossification, sequelae of surgical
procedures,9,58 and the presence of metallic or other
radiodense implants, which can produce artefacts that
skew the result of the scan. Patients with SB are likely
to have contractures that preclude positioning of the
spine or hip scans.24,54,57 The absence of posterior
elements in the vertebrae of SB patients artificially
lowers the BMD of the lumbar spine, which must be
taken into account when interpreting the DXA scan.53
Sites that are fractured should be excluded from evalu-
ation because disuse osteopenia and increased density
from exuberant fracture calluses will not give an accu-
rate picture of overall bone health.57
Low femoral neck BMD in children with sacral-level
MMC and minimal gait impairments may be due to
generalized hip-area weakness from poor innervation
of the sacral-level gluteal muscles25 and would not be
useful for identifying patients who are more likely to
suffer a fracture.
The distal lateral femoral scan is of unequivocal
importance in paediatric patients with SB because this
area is the most common fracture site.4,24 Because it
can be evaluated in children with significant
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contractures, the distal lateral femoral scan is likely to
replace femoral neck measurement in children with dis-
abilities.24,25,54,57 Reference Z-scores for the distal
lateral femur are available for children aged 3 years and
older.54
Probability-based assessment of fracture in
SB patients
The striking question is how to identify children with SB
with a high fracture risk through their clinical character-
istics to prevent fractures. A defined protocol could alert
the physician to the risk of new fractures following pro-
longed immobilization and could reduce the subsequent
risk of the fracture–plaster–fracture cycle. The manner
in which clinical risk factors have been used to identify
high-risk individuals has not yet been validated.
Currently, there is no tool to predict BMD in paediatric
patients. Because it would not be cost effective to univer-
sally screen for BMD in children with SB, the guidance
should be based on an opportunistic case-finding strat-
egy in which physicians are alerted to the possibility of
osteoporosis and high fracture risk by the presence
of clinical risk factors associated with fracture.59
Although several studies have been conducted to
assess BMD in paediatric populations, there is no con-
sensus for predicting fracture risk,41,47,57,60 particularly
in those with chronic conditions45 such as SB.7,11,25
The misunderstood concept of paediatric
osteoporosis and its limitations
The ISCD proposed that the diagnosis of osteoporosis in
children and adolescents should require a clinically sig-
nificant fracture history and a decreased BMD. A clini-
cally significant fracture history includes one or more of
the following: a long-bone fracture of a lower-extremity,
vertebral compression fracture, or two or more long-
bone fractures of the upper extremities. Low BMD is
defined as a Z-score less than or equal to −2.0, adjusted
for age, gender, and body size.47 According to some
authors, osteoporosis can be suspected clinically in
patients who suffer a low-impact fracture.61,62 Both the
emphasis on the presence of fracture by the definition
of osteoporosis used by the ISCD47,63 and the impor-
tance of clinical bone fragility to some authors in diag-
nosing osteoporosis is appropriate given the challenges
of interpreting densitometry in children.57,61 Thus,
unlike in adults, the diagnosis of osteoporosis in children
depends on a history of fracture.47,62,63 In patients with
SB, waiting for the first fracture is counterproductive in
maintaining bone health, and efforts should be directed
at earlier prevention.
Prevention and non-pharmacological and
pharmacological treatment of osteoporosis
Initial treatment for low bone mass and fractures in chil-
dren is directed towards reducing or eliminating modifi-
able skeletal risk factors.47,61 To prevent fractures
secondary to postoperative inactivity,4 surgeons rec-
ommend several interventions combined in one surgical
procedure or at least within a certain period during
which the patient needs to be immobilized.6 The
period of immobilization after a surgical intervention
should be reduced, if possible,6,15 and weight-bearing
should be allowed as soon as possible,1,10 depending
on X-rays signs of consolidation.10 There is limited evi-
dence that passive weight-bearing in children with SB
improves BMD,25 although standing with the use of a
standing frame appears to increase BMD in children
with cerebral palsy.64 In a double-blinded, prospective,
randomized, placebo-controlled study including 20
ambulant children with disabilities but no mention of
the diagnosis of each child, Ward and colleagues
observed that low-magnitude, high-frequency mechan-
ical stimuli increase tibial and spinal volumetric trabecu-
lar BMD.65
Data from physical therapy research,66 including
investigations of standing on vibrating platforms65 in
children with disabilities, suggest that gains in bone
mass may occur with even modest increases in skeletal
loading, but these studies are subject to methodological
criticisms because of the small number of patients
included and the use of different parameters that
prevent comparisons between programmes. We must
also consider that the bone response in children with
flaccid paralysis could be different from others con-
ditions, such as cerebral palsy, implying that studies
are needed to clarify the effects of standing in a standing
frame and on vibrating platforms on patients with SB.
Liptak et al. analysed 39 children who used a parapo-
dium and 29 children in wheelchairs with MMC in a
comparative study and showed that early use of the
parapodium did not protect against fractures.37 The
most ideal mobility device remains controversial.
Weight bearing during ambulation should not be con-
fused with passive weight bearing using a device, such
as a standing frame.25 To determine whether it is worth-
while to encourage patients who have high-level SB to
walk at an early age, Mazur and colleagues compared
36 patients who participated in a walking programme
with 36 patients matched for age, sex, level of lesion,
and intelligence for whom a wheelchair was prescribed
early in life. The patients who walked earlier had fewer
fractures.33 Ausili et al. showed that BMD in the
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lumbar and femoral neck regions was improved in
MMC patients who participated in athletic activities in
comparison with those who did not.26
No studies are available concerning the amount of
weight bearing and ambulation necessary to maintain
or increase BMD10 to guide prescription of this treat-
ment in patients with SB.
For paediatric patients who fail to respond adequately
to these general measures, pharmacological therapy for
osteoporosis may be considered. Few studies have eval-
uated the effect of pharmacological treatment on BMD
and fractures in patients with SB.
Global programmes should include attention to nutri-
tional factors, particularly adequate intake of calcium
and vitamin D. The impairment in ambulation and
functioning in paediatric patients with SB may cause
them to spend more time inside, which may increase
the risk for low serum calcidiol and osteopenia. Non-
ambulatory children and children with frequent frac-
tures and low BMD should be considered for routine
monitoring of risk and vitamin D deficiency screen-
ing.67,68 During adolescence, when dairy consumption
decreases, vitamin D intake is less likely to be adequate,
and this deficiency may adversely affect calcium absorp-
tion.9 A review of controlled trials documented an
increase in the BMC of adolescents who took calcium
supplements.69 However, constipation secondary to neu-
ropathic bowel is a frequent problem in patients with SB,
and supplementation with calcium may exacerbate it.
This side effect should be considered, and treatment of
constipation in MMC children should be given when
appropriate.70 Moreover, patients with MMC have
hypercalciuria linked to immobilization,11 which is a
known metabolic risk factor associated with renal
calculi. Matlaga et al. have established that many patients
with MMC undergoing percutaneous nephrolithotomy
will be found to have calculi that are metabolically
derived rather than calculi secondary to chronic bacter-
iuria with urea-splitting organisms.71 Consequently, in
patients with SB, metabolic calculi may be exacerbated
by oral calcium administration. Restriction of dietary
calcium is not recommended in children with hypercal-
ciuria, as it puts the growing child at risk for negative
calcium balance and poor bone mineralization.72
Hypercalciuria was also found in 43% of children with
recurrent urinary tract infection.73
Therapy for bone fragility in childhood has been
limited to conservative measures, such as optimizing
calcium and vitamin D intake, even though adequate
calcium and vitamin D intake may not be enough to
treat osteoporosis,74 particularly in patients with a high
fracture risk. To date, no outcome study on the use of
vitamin D has proven convincingly that this vitamin is
insufficient for patients with a high fracture risk. Thus,
the impact of vitaminD on BMD is currently unknown.25
Hydrochlorothiazide is known to reduce urinary
calcium loss and increase BMD in non-MMC
patients,75,76 and a positive association between hyper-
calciuria and fractures has been identified in SB
patients.11 In a prospective randomized, double-
blinded controlled study of 20 children with MMC
with ages ranging from 6 to 16 years, Quan et al.
recorded no positive effects of hydrochlorothiazide on
forearm BMD compared to placebo-treated controls,
despite a tendency for decreased urine calcium
excretion.34 However, only 13 of the patients completed
the year-long protocol, and only six patients belonged to
the hydrochlorothiazide group. Thus, at this time, it is
unknown as to whether pharmacological therapy with
hydrochlorothiazide increases BMD.
Reducing hypercalciuria has occasionally been the aim
of bisphosphonate therapy even in patients with normal
calcium concentrations77 and is being considered with
increasing frequency in children with secondary osteo-
porosis. In a case series, Sholas et al. analysed the
effects of oral alendronate in 10 non-ambulatory children
(one with SB) aged 3–17 years. This study showed that
disabled, non-ambulatory children tolerate alendronate,
and it may decrease fractures in those at risk of severe
disuse osteopenia.35 A similar conclusion was drawn
from a retrospective, uncontrolled trial by Steelman
et al., who used a single-day low-dose pamidronate infu-
sion every 3 months. Pamidronate treatment increased
BMD and decreased the fracture rate of symptomatic
paediatric osteoporotic patients (n= 18) aged 6–21
years with only one of whom had SB.36
Low BMD among children may not indicate acceler-
ated bone loss41 but rather a failure to achieve the
expected peak bone mass, bone loss or a combination
of the two.78,79 It is important to acknowledge that the
use of antiresorptive drugs, such as bisphosphonates,
may not be the optimal approach. Therefore, an under-
standing of the pathogenesis of low bone mass in pae-
diatric patients with SB is needed.41 In this way, in
children who fail to gain adequate bone mineral,41
PTH would be an alternative because it is the most effec-
tive anabolic agent for bones in adults.61 However, PTH
has a black box warning against its use in children and
adolescents because it has caused osteosarcoma in a sig-
nificant proportion of young rats.80 The previously men-
tioned study by Quan et al. demonstrated that full-time
wheelchair users and limited ambulators had elevated
urinary pyridinoline and thus greater bone reabsorption
compared to normal ambulatory patients.5 This finding
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could differentiate the pathophysiological mechanisms
involved in osteoporosis in this population from other
cases of paediatric osteoporosis, and it suggests a poten-
tial beneficial role for bisphosphonates. However, the
potential benefits of bisphosphonate therapy should be
analysed and weighed against the potential adverse
effects. Flu-like symptoms in children can occur with
the initiation of bisphosphonates.81 Some of the most
serious side effects associated with bisphosphonates,
such as uveitis and thrombocytopenia and oesophageal
or oral ulcerations, which were documented in adult
studies, are rare in children.61 The gastrointestinal symp-
toms associated with oral agents should be weighed in
patients with SB because the Arnold-Chiari II malfor-
mation can compromise deglutition. Munns and col-
leagues have described adverse respiratory events
associated with the first pamidronate cycle in four
infants with severe osteogenesis imperfecta who were
less than 2 years of age with pre-existing reactive airway
disease.82 In excess, bisphosphonates can induce the over-
suppression of bone turnover83 and can cause acute post-
infusion hypocalcemia and hypophosphatemia.84
Iatrogenic osteopetrosis was detected in a child who was
treated for 234 years with more than four times the usual
pamidronate dosage.83 In children with osteogenesis
imperfecta, pamidronate disodium has been associated
with an increased risk of delayed osteotomy healing.85
Osteonecrosis of the jaw has been described among
adults; however, there were no cases identified in children
receiving bisphosphonates.61,74,86 Extrapolating the litera-
ture from other diagnoses87,88 and reviewing clinical
experiences suggest a potential benefit of using bispho-
sphonates in paediatric patients with SB; however, bispho-
sphonates are neither the current standard of care nor are
they approved by the United States Food and Drug
Administration for this purpose.25,41 Moreover, there is
no literature detailing which factors should be used to
determine the suitable length of pharmacological treat-
ment after bisphosphonate treatment is initiated.61,89
To our knowledge, there are no studies evaluating the
use of calcitonin in SB treatment. This polypeptide has
been confirmed to be more effective in preventing ver-
tebral fractures than hip fractures in patients with osteo-
porosis.90 Therefore, it may not be the first treatment
option of choice for patients with MMC, in which frac-
tures are more common in the lower extremities. Also,
the lack of documentation of vertebral fractures suggests
a possible protective effect on vertebral fractures among
patients with SB who use wheelchairs.4,12
Most of the articles identified had small sample sizes and
lacked the scientific power of clinical trials. No studies of
paediatric patients with SB compare two different
methods of osteoporosis treatment (pharmacological vs.
non-pharmacological) and two pharmacological agents.
Practice points and recommendations for
research
While recognizing the uncertainties and limitations of
the studies concerning fracture and osteoporosis in pae-
diatric patients with SB, we can draw some conclusions
that can be useful for physicians involved in the care of
children with SB. Children with SB should have their
fracture risk evaluated at each consultation by the
medical team. Thus, calcium and vitamin D intake
should be evaluated by the physician. In the presence
of vitamin D deficiency and/or poor dietary calcium
intake, it would be suitable to replace such deficits,
but routine calcium and vitamin D supplementation is
not recommended.10,91 Weight bearing during ambu-
lation and sports activity should also be stimulated
because it may reduce fractures33 and increase BMD26
in MMC, respectively. If a fragility fracture occurs
despite vitamin D supplementation and physiotherapy,
no guidelines are available for further management.
Future issues to be addressed concerning the issue of
osteoporosis in children with SB include a determination
of what and how many specific processes underlie this
condition. Research should establish a relationship
between low BMD and fracture risk.25 Currently, there
is no universal treatment regimen for osteoporosis in
SB. The experience of world centres specialized in treat-
ing children with SB who suffer from multiple fractures
or osteoporosis has not been disseminated, which makes
it impossible to compare data among different centres.
Thus, there is a need to properly evaluate the efficacy
of non-pharmacological and pharmacological osteo-
porosis treatment through randomized clinical trials.
Who should be treated and the appropriate duration
of treatment are not well known. Whether low BMD
alone is adequate for drug therapy in children is far
less clear. We think that bone fragility is a critical area
for future research in SB.
Conclusion
Paediatric patients with SB are at risk of
fractures1,3,4,6,10–16,18,20–23 and low BMD.25 The risk
factors for fractures include higher level neurological
involvement,1,4,10,14,15 non-ambulatory status,4,10 con-
tractures,14 hypercalciuria,11 higher body fat levels,11
postoperative inactivity,1,3,4,6,10,13,15,16,18,20–22 and a pre-
vious spontaneous fracture.4 There is no evidence to
substantiate measuring BMD to evaluate fracture prob-
ability in paediatric patients with SB. Serious limitations
were observed in the number and quality of studies
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concerning osteoporosis prevention and treatment in
paediatric patients with SB.
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